logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
返回期刊详情
D

diabetes, obesity and metabolism

IF
论文数538
被引数
期刊论文 538
发表时间
delete
Supporting Weight Management for Kidney Transplant Candidates in People With Obesity on Haemodialysis: The First National Survey of UK Kidney Healthcare Providers为接受血液透析的肥胖患者中的肾移植候选者提供体重管理支持：英国肾健康护理提供者的首次全国调查
deletediabetes, obesity and metabolism
IF0
delete2026-05-31
delete0
deleteOAAI
deleteAdrian Brown; Helen L. MacLaughlin; Kieran McCafferty; Sebastian Potthoff; Sharlene Greenwood; Victoria Vickerstaff; Rachel L. Batterham; Rachel Thomas; Claudia Hobbs; Reza Motallebzadeh
delete分享
delete收藏
GLP-1 RA Therapy After Bariatric Surgery: Phenotype, Strategy and Success减重手术后GLP-1 RA疗法：表型、策略与疗效
deletediabetes, obesity and metabolism
IF0
delete2026-05-31
delete0
PREAI
deleteMan Sun; Dan Zang; Jun Chen
delete分享
delete收藏
Inflammatory Cytokines Impair Glucagon Expression and Secretion in Pancreatic α-Cells炎症细胞因子损害胰腺α细胞中的胰高血糖素表达和分泌
deletediabetes, obesity and metabolism
IF0
delete2026-05-31
delete0
deleteOAAI
deleteCaroline Bickelmann; Cedric Wilden; Leticia Prates-Roma; Matthias W. Laschke; Emmanuel Ampofo; Selina Wrublewsky
delete分享
delete收藏
From Induction to Maintenance? Rethinking GLP-1–Based Obesity Pharmacotherapy in the Era of Oral Agents从诱导到维持？在口服药物时代重新思考基于GLP-1的肥胖症药物治疗
deletediabetes, obesity and metabolism
IF0
delete2026-05-31
delete0
PREAI
deleteA. B. M. Kamrul-Hasan; Deep Dutta; Kunal Mahajan; Lakshmi Nagendra; Joseph M. Pappachan; Saptarshi Bhattacharya; Sanjay Kalra
delete分享
delete收藏
Unveiling the BMI Risk Threshold for Osteoarthritis: Multi-Database Causal and Nonlinear Evidence揭示骨关节炎的BMI风险阈值：多数据库因果和非线性证据
deletediabetes, obesity and metabolism
IF0
delete2026-05-31
delete0
deleteOAAI
deleteShaohong Yu; Li Zeng; Lei Yang; Yangjiang Ou; Chenglin Yang; Xiaoru Lin; Jingyi Shao; Qing Guan; Guobo Li; Xiuquan Lin
delete分享
delete收藏
Trends in Potentially Avoidable Hospitalisations Among People With Diabetes in Ireland; 2015–20242015–2024年爱尔兰糖尿病患者中潜在可避免住院的趋势
deletediabetes, obesity and metabolism
IF0
delete2026-05-31
delete0
deleteOAAI
deleteJennifer A. Pallin; Naomi Holman; Kevin McIntyre; Diarmuid Smith; Seamus Sreenan; Michael Lockhart; Lisa Devine; Claire M. Buckley; Edward W. Gregg
delete分享
delete收藏
Adding Finerenone to SGLT2 Inhibitors and Long-Term Kidney Outcomes in Diabetic Kidney Disease在糖尿病肾病中添加非奈利酮到SGLT2抑制剂与长期肾脏结局
deletediabetes, obesity and metabolism
IF0
delete2026-05-31
delete0
PREAI
deleteMasaru Matsui; Masatoshi Nishimoto; Takaaki Kosugi; Shunsuke Kitamura; Aiko Oda; Masato Kawakami; Akiko Itano; Takayuki Uemura; Hiroyuki Tamaki; Hikari Tasaki; Keisuke Okamoto; Masahiro Eriguchi; Ken-ichi Samejima; Kazuhiko Tsuruya
delete分享
delete收藏
Cardiovascular Disease Risk Prediction in Patients With Metabolic Dysfunction-Associated Steatohepatitis代谢功能障碍相关脂肪性肝炎患者心血管疾病风险预测
deletediabetes, obesity and metabolism
IF0
delete2026-05-31
delete0
deleteOAAI
deleteJoe Hollinghurst; Margarida Augusto; Fotis Tefos; Robert Bauer; Sreelatha Vadapalle; Lise Gehrt Cardél
delete分享
delete收藏
Evaluation of the Safety, Efficacy and Pharmacokinetics of BGM0504 in Chinese Adults With Type 2 Diabetes: A Multicentre, Randomised, Controlled and Double-Blind Phase II Trial评价BGM0504在中国2型糖尿病成人中的安全性、有效性和药代动力学：一项多中心、随机、对照和双盲II期试验
deletediabetes, obesity and metabolism
IF0
delete2026-05-31
delete0
deleteOAAI
deletePing Jin; Linong Ji; Yangqing Huang; Haifeng Ding; Daosheng Xie; Xiaohui Jiang; Xuemei Yuan; Zhao Cao; Haibin Zhang; Jiandong Yuan
delete分享
delete收藏
The Effect of Canagliflozin Dose on Renal and Cardiovascular Outcomes in Type 2 Diabetes and High Cardiovascular Risk坎格列净剂量对2型糖尿病及高风险心血管患者肾功能和心血管结局的影响
deletediabetes, obesity and metabolism
IF0
delete2026-05-31
delete0
deleteOAAI
deleteElias John Elenjickal; Frédéric Baroz; Philippe Boileau; Michael A. Tsoukas; Abhinav Sharma; Thomas A. Mavrakanas
delete分享
delete收藏
Impact of Sleeve Gastrectomy Versus Intensive Lifestyle Modifications With Obesity Management Medications on BMI Trajectory and Target Attainment: A Prospective Matched Cohort Study袖状胃切除术与高强度生活方式干预联合肥胖管理药物对BMI轨迹和目标达成的影响：一项前瞻性匹配队列研究
deletediabetes, obesity and metabolism
IF0
delete2026-05-31
delete0
deleteOAAI
deleteMaria Francesca Russo; Giovanni Casella; Giulia Angelini; Sara Russo; James Casella-Mariolo; Vito D'Andrea; Giulio Illuminati; Lidia Castagneto-Gissey
delete分享
delete收藏
The Impact of GLP-1-Based Therapies on Cardiovascular Outcomes in Type 2 Diabetes: A Comprehensive Systematic Review and Network Meta-AnalysisGLP-1基治疗对2型糖尿病心血管结局的影响：一项全面的系统评价和网络Meta分析
deletediabetes, obesity and metabolism
IF0
delete2026-05-31
delete0
PREAI
deleteShih-Ming Chuang; Sung-Chen Liu; Kuo-Liong Chien; Cheng-Jui Lin; Ming-Chieh Tsai; Hong-Mou Shih
delete分享
delete收藏
Semaglutide Injection in Indian Patients With Type 2 Diabetes Mellitus: A Randomised, Phase III, Active-Controlled Study司美格鲁肽注射液治疗印度2型糖尿病患者的随机、III期、活性对照研究
deletediabetes, obesity and metabolism
IF0
delete2026-05-31
delete0
deleteOAAI
deleteUnnikrishnan Ambika Gopalakrishnan; Ameya Sudhakar Joshi; Richa Giri; Shalin Jagdeep Shah; Jitendra Shukla; Sanjiv Maheshwari; Rekha M. Chowdaiah; Manish Kumar Singh; Aditya Srirang Bari; Niranjan Pandurang Pathak; Akash Nitinbhai Shah; Shweta Bhandari; Ambanna Gowda; Ambrish Chandrappa; Pravin Dinkar Supe; Bharat Das; Prabhat Kumar Sharma; Mehul Kalubhai Virani; Prakash Harishchandra Kurmi; Gayatri Amit Ghanekar; Mani Deepathi Dasari; Banshidhar Sahoo; Sanjay Kumar Jangid; Prakash Sadashiv Shende; Sandesh Sahebarao Patil; Avinash Narayan Kumbhar; Shrikant Vishnu Deshpande; Madhusudhan Chennappa; Nitesh Chandubhai Patel; Dipesh Sonawane; Dipak Patil; Sucheta Pandit; Pravin Ghadge; Suyog Mehta
delete分享
delete收藏
GIP in Cardiovascular and Kidney Disease: From Physiology to Pharmacology心血管和肾脏疾病中的GIP：从生理学到药理学
deletediabetes, obesity and metabolism
IF0
delete2026-05-28
delete0
deleteOAAI
deleteMichelantonio De Fano; Line L. Haurum; Christine R. Schwarz; Francesca Porcellati; Andreas Andersen
delete分享
delete收藏
Association of Physical Activity With All-Cause and CVD Mortality Across Metabolic and Obesity Phenotypes身体活动与不同代谢和肥胖表型下全因及心血管疾病死亡率的关联
deletediabetes, obesity and metabolism
IF0
delete2026-05-28
delete0
deleteOAAI
deleteYunmin Han; Younghwan Choi; Soomin Lee; Yeon Soo Kim
delete分享
delete收藏
Risk of Psychiatric Worsening With GLP-1 Receptor Agonist Use in Patients With Type 2 Diabetes and Treated DepressionGLP-1受体激动剂在伴有2型糖尿病和治疗性抑郁症患者中导致精神症状恶化的风险
deletediabetes, obesity and metabolism
IF0
delete2026-05-28
delete0
deleteOAAI
deleteYu Chang; Ming-Hong Hsieh; Po-Chung Ju; Cheng-Chen Chang
delete分享
delete收藏
Young People With Type 2 Diabetes Are Under-Represented in Randomized Clinical Trials2型糖尿病青年人在随机临床试验中代表性不足
deletediabetes, obesity and metabolism
IF0
delete2026-05-28
delete0
deleteOAAI
deleteBowei Yu; Juliana C. N. Chan; Andrea O. Y. Luk; Hongjiang Wu
delete分享
delete收藏
Weight Management With Semaglutide and Tirzepatide in U.S. Adults: Projected Impact on Obesity Prevalence and Heart Failure Risk使用司美格鲁肽和替尔泊肽进行体重管理在美国成人中的效果：对肥胖患病率和心力衰竭风险的预测影响
deletediabetes, obesity and metabolism
IF0
delete2026-05-28
delete0
PREAI
deleteHailey Choi; Andrew Y. Hwang
delete分享
delete收藏
Impact of Removing Restrictive Haemoglobin A1C Eligibility Criteria for Insulin Pump Therapy Funding for Children With Type 1 Diabetes in Ontario, Canada移除加拿大安大略省儿童1型糖尿病胰岛素泵疗法资助中限制性糖化血红蛋白A1C资格标准的影响
deletediabetes, obesity and metabolism
IF0
delete2026-05-28
delete0
deleteOAAI
deleteAlanna Weisman; Karl Everett; Peter C. Austin; Rayzel Shulman
delete分享
delete收藏
A Phase 2 Trial of Frexalimab, a CD40L Antagonist, in Adolescents and Adults With Recent-Onset Type 1 Diabetes (FABULINUS): Rationale and Study Design一项Frexalimab（一种CD40L拮抗剂）在近期发病的1型糖尿病青少年和成人中的2期试验（FABULINUS）：研究依据和试验设计
deletediabetes, obesity and metabolism
IF0
delete2026-05-27
delete0
deleteOAAI
deleteAndriy Cherkas; Baerbel Rotthaeuser; Niels Porksen; Pascale Labard; My-Liên Nguyên-Pascal; Mathieu Coudert; Baptiste Berthou; Marie Baccara-Dinet; Gabor Boka; Mark Peakman; Felix Reschke; Michael J. Haller
delete分享
delete收藏